Mumbai: Pharma major Wockhardt is planning to launch Italy’s B-Lift range of dermatology products in India during the third quarter of this year.
Wockhardt has signed its first in-licensing agreement in the anti-wrinkle arena with Milan-based Syrio Pharma SPA to market its B-Lift range of dermatology products, the company informed the Bombay Stock Exchange.
B-lift would be available in a wide range, including a topical application gel for men. The B-Lift range of products, are based on a Botox like peptide. However, B-Lift, unlike Botox, is available in gel form and can be used on all patients. It is also known to have a better safety profile than Botox.
“Wockhardt has always strived to introduce newer and better products for the benefit of Indian patients,” Wockhardt chairman Habil Khorakiwala said, adding that “We will soon introduce the B-Lift range of products to cater to patients seeking advanced skin renewal treatment in India.”
According to market analysts, the anti-ageing market in India is estimated at Rs 200 crore and with growing awareness and lifestyle changes, this figure could grow exponentially.
The company plans to enter this market with an independent field force. In future, all the skin care brands of Wockhardt would be launched through this speciality team.
Last week, Wockhardt announced its plans to launch a patented silicon gel, Kelocote, for treatment of scars and keloids in India by third quarter of this year and had entered into an in-licensing pact with US-based firm Advanced Biotechnologies Inc to market the gel in India.